CNS Pharmaceuticals to Host Shareholder Webinar Today to Discuss Coronavirus Collaboration, the Significance of WP1244, and an Update on the Cancer Free Survivor Treated with Berubicin

HOUSTON, April 22, 2020 /PRNewswire/ — CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biotechnology company specializing in the development of novel treatments for brain tumors, announced that CEO, John M. Climaco, will be issuing a shareholder webinar on April 22nd, 2020 at 4:30pm ET to discuss the Company’s novel DNA-binding agent, WP1244, and to provide an update on both the development of WP1122 through its strong relationship with WPD Pharmaceuticals in Poland, and a glioblastoma survivor treated with Berubicin.

The release as fetched from its publisher. cnspharma.com ↗